ES2402095T3 - Genes y productos de expresión génica que son regulados en forma diferencial en el cáncer de próstata - Google Patents

Genes y productos de expresión génica que son regulados en forma diferencial en el cáncer de próstata Download PDF

Info

Publication number
ES2402095T3
ES2402095T3 ES04015121T ES04015121T ES2402095T3 ES 2402095 T3 ES2402095 T3 ES 2402095T3 ES 04015121 T ES04015121 T ES 04015121T ES 04015121 T ES04015121 T ES 04015121T ES 2402095 T3 ES2402095 T3 ES 2402095T3
Authority
ES
Spain
Prior art keywords
polynucleotide
sequence
sequences
prostate
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04015121T
Other languages
English (en)
Spanish (es)
Inventor
Jon H. Astel
Eddie Carroll, Iii.
Wilson O. Endege
Donna M. Ford
John E. Monahan
Robert Schlegel
Kathleen E. Steinmann
Jimmy Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of ES2402095T3 publication Critical patent/ES2402095T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES04015121T 1998-06-11 1999-06-10 Genes y productos de expresión génica que son regulados en forma diferencial en el cáncer de próstata Expired - Lifetime ES2402095T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US328475 1994-10-25
US8887798P 1998-06-11 1998-06-11
US88877P 1998-06-11
US09/328,475 US6476207B1 (en) 1998-06-11 1999-06-09 Genes and gene expression products that are differentially regulated in prostate cancer

Publications (1)

Publication Number Publication Date
ES2402095T3 true ES2402095T3 (es) 2013-04-26

Family

ID=26779140

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04015121T Expired - Lifetime ES2402095T3 (es) 1998-06-11 1999-06-10 Genes y productos de expresión génica que son regulados en forma diferencial en el cáncer de próstata

Country Status (5)

Country Link
US (2) US6476207B1 (https=)
EP (1) EP1086218A2 (https=)
JP (1) JP2002517244A (https=)
ES (1) ES2402095T3 (https=)
WO (1) WO1999064594A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
AU5134600A (en) * 1999-05-14 2000-12-05 Incyte Genomics, Inc. Full-length molecules expressed in human tissues
US20020168638A1 (en) * 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
CA2402834A1 (en) * 2000-03-23 2001-09-27 Immusol Incorporated Brca-1 regulators and methods of use
WO2001073030A2 (en) * 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2001287269A1 (en) * 2000-03-28 2001-10-08 Chiron Corporation Human genes and expression products
AU2001285047A1 (en) * 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
EP1847620A3 (en) * 2000-10-13 2008-10-22 Cedars-Sinai Medical Center Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
MXPA03004637A (es) * 2000-11-28 2003-09-05 Wyeth Corp Analisis de expresion de acidos nucleicos y polipeptidos kiaa utiles en diagnostico y tratamiento de cancer de prostata.
CA2430794A1 (en) * 2000-12-07 2002-07-18 Chiron Corporation Human genes and gene expression products isolated from human prostate
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
AUPS187002A0 (en) * 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
KR20060073589A (ko) * 2003-08-07 2006-06-28 카이론 코포레이션 항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3)
CA2555866A1 (en) * 2004-02-16 2005-08-25 Proteosys Ag Diagnostic markers for cancer
US7657383B2 (en) * 2004-05-28 2010-02-02 International Business Machines Corporation Method, system, and apparatus for compactly storing a subject genome
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
EP3640329A1 (en) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Gene editing based cancer treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
WO1996006951A1 (en) * 1994-08-31 1996-03-07 The Johns Hopkins University School Of Medicine Detection of hypermutable nucleic acid sequence in tissue
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5767258A (en) * 1995-05-12 1998-06-16 The Johns Hopkins University School Of Medicine Cell cycle regulatory gene
US5594402A (en) * 1995-06-02 1997-01-14 International Power Group, Inc. High voltage isolating transformer module
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5861248A (en) * 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
JP2002511734A (ja) * 1996-11-21 2002-04-16 シーダーズ―サイナイ・メディカル・センター 下垂体―腫瘍―形質転換遺伝子及び関連生成物

Also Published As

Publication number Publication date
WO1999064594A8 (en) 2000-06-02
WO1999064594A2 (en) 1999-12-16
JP2002517244A (ja) 2002-06-18
US20020192699A1 (en) 2002-12-19
WO1999064594A3 (en) 2000-08-17
US6476207B1 (en) 2002-11-05
WO1999064594A9 (en) 2000-10-12
EP1086218A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
ES2402095T3 (es) Genes y productos de expresión génica que son regulados en forma diferencial en el cáncer de próstata
JP3844366B2 (ja) 前立腺ガンの免疫診断のための化合物およびそれらの使用方法
JP6434444B2 (ja) 腫瘍の診断と治療を目的とした表面会合抗原の同定
JP2002519000A (ja) ヒト遺伝子および遺伝子発現産物ｉｉ
JP2002500010A (ja) ヒト遺伝子および遺伝子発現産物ｉ
JP2003518920A (ja) 新規なヒト遺伝子および遺伝子発現産物
US20060179496A1 (en) Nucleic acid sequences differentially expressed in cancer tissue
JP2004512029A (ja) ヒト遺伝子および遺伝子発現産物
JPH11505322A (ja) Ｔｇｆ−ベータリセプター中の変異に基づく癌の診断および治療
JP2002534055A (ja) ヒト遺伝子および遺伝子発現産物ｖ
JP2004502406A (ja) ヒト遺伝子およびヒト遺伝子発現産物
EP0822993B1 (en) Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene kai1
Wang et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma
ES2344179T3 (es) Genes expresados diferencialmente en cancer pancreatico y displasia.
JP2005517395A (ja) ヒト前立腺から単離したヒト遺伝子および遺伝子発現産物
US20040110712A1 (en) Methods for treating patients and identifying therapeutics
ES2305087T3 (es) Polinucleotidos relacionados con el cancer de colon.
EP1399584A2 (en) Cancer-linked genes as targets for chemotherapy
US20040234979A1 (en) Differentiall-expressed and up-regulated polynucleotides and polypeptides in breast cancer
JP2003530816A (ja) ヒト遺伝子および遺伝子発現産物
EP1466988B1 (en) Genes and gene expression products that are differentially regulated in prostate cancer
JP2004526429A (ja) ヒト前立腺から単離したヒト遺伝子および遺伝子発現産物
ES2316501T3 (es) Moleculas marcadoras asociadas con tumores pulmonares.
CA2416285A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
JP2009195236A (ja) 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法